Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Extension Study of WVE-210201 in Patients Previously Enrolled in WVE-DMDX51-001

Next Previous
Trial Profile

A Multicenter, Open-Label Extension Study of WVE-210201 in Patients Previously Enrolled in WVE-DMDX51-001

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Suvodirsen (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Sponsors WaVe life Sciences

    • Most Recent Events

    • 29 Jul 2019 According to a WaVe life Sciences media release, In June, interim data (N=25, data cut off- June 18, 2019) were reported at the 2019 Parent Project Muscular Dystrophy (PPMD) Annual Conference.
    • 29 Jul 2019 According to a WaVe life Sciences media release, data from an interim analysis are expected in 4Q 2019. This interim analysis will include dystrophin expression from muscle biopsies taken 22 weeks after patients enrolled in the OLE were transitioned to one of the Phase 2/3 doses of suvodirsen, as well as a safety summary.
    • 12 Jun 2019 According to a WaVe life Sciences media release, data from interim analysis of this study is used for submission to the U.S. Food and Drug Administration (FDA) for accelerated approval in the United States in the second half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top